Nunzia Pharmaceutical Company

NUNZ

US67097W1027

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 06:40:00 02/12/2023 am IST			5-day change	1st Jan Change
0.003 ^USD	-.--%		-.--%	-.--%

2022	Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

NUNZIA PHARMACEUTICAL CO : Entry into a Material Definitive Agreement (form 8-K)

March 02, 2022 at 09:48 pm IST

Item 1.01 Entry into a Material Definitive Agreement.

On February 22 ,2022 ALL of the board members accepted the resignation of Charles Strongo as CEO and Chairman of NUNZIA PHARMACEUTIACL due to personal reasons. After his sabbatical is over, he may request to come back.

--------------------------------------------------------------------------------

Latest news about Nunzia Pharmaceutical Company

Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	03/22/03	CI
Nunzia Pharmaceutical Company Reports Earnings Results for the First Quarter Ended March 31, 2022	23/22/23	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI
Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	15/22/15	CI
Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	29/22/29	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	10/21/10	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/21/16	CI
Nunzia Pharmaceutical Corporation Announces Offering of Patented Blood Warmer Through Medical Supply Division	16/21/16	CI
Nunzia Pharmaceutical Corporation Signs A Licensing Agreement with Michael Mitsunaga	06/21/06	CI
Global WholeHealth Partners Corporation acquired distribution and selling rights of Moderna Vaccine of Nunzia Pharmaceutical Corporation.	25/21/25	CI
Global Wholehealth Partners Corporation Partners with Nunzia Pharmaceutical Inc. to Distribute and Sell the Pfizer-BioNTech COVID-19 Vaccine	16/21/16	CI
Global Wholehealth Partners Corporation Grants the Rights from Nunzia Pharmaceutical Inc. to Distribute and Sell the Johnson & Johnson Covid-19 Vaccine	10/21/10	CI
Global Wholehealth Partners Corp. Partners with Nunzia Pharmaceutical Inc., Opening New Avenues of Revenue and Products for Global	22/21/22	CI
Global Wholehealth Partners Corporation Enters into Mutual Sales and Marketing Agreement with Nunzia Pharmaceutical Inc	19/21/19	CI
Global WholeHealth Partners Corp Receives from Nunzia Pharmaceutical the Full Right as Distributor of Nunzia to Sell the ADZ 1222 Covid 19 Vaccine by Thameen Healthcare Trading LLC	08/21/08	CI
Nunzia Pharmaceutical Corporation Launches New Version of its Already Acclaimed NUNZIA Nutraceutical	16/20/16	CI
Nunzia Pharmaceutical Corporation Announces Availability of Nunzia Nutraceutical to Market	01/20/01	CI
Arizona Gold and Onyx Mining Company will Change its Name to Nunzia Pharmaceutical Corporation	04/19/04	CI
Nunzia Pharmaceutical Corporation will Change its Ticker to VGCP.D from VGCP	04/19/04	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	03/19/03	CI

Chart Nunzia Pharmaceutical Company

Duration

Period

More charts

Company Profile

Nunzia Pharmaceutical Corporation is a pharmaceutical company. The Company focuses on development and delivery of pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum of Disorders (ASDs) and related conditions, such as Fragile X syndrome, as well as common anxiety-based disorders. The Company has developed NUNZIA, which is a combination of 16 vitamins, minerals and herbs which directly focuses and targets the hippocampus area of the brain, where all anxiety-based disorders originate.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NUNZIA PHARMACEUTICAL COMPANY	-.--%	13.04L
ELI LILLY AND COMPANY	+40.73%	74TCr
NOVO NORDISK A/S	+32.83%	60TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
NOVARTIS AG	+9.78%	21TCr
ROCHE HOLDING AG	-5.52%	21TCr
AMGEN INC.	+6.17%	16TCr

Other Pharmaceuticals

Nunzia Pharmaceutical Company

Equities

NUNZ

US67097W1027

Pharmaceuticals

NUNZIA PHARMACEUTICAL CO : Entry into a Material Definitive Agreement (form 8-K)

Latest news about Nunzia Pharmaceutical Company

Chart Nunzia Pharmaceutical Company

Company Profile

Sector Other Pharmaceuticals